A Comparative Study on the Review and Evaluation of the Regulatory Process of Spurious and not Standard Quality Drugs in Different Countries
Future Journal of Pharmaceuticals and Health Sciences · 18.10.2023 · 3 (4) · 441-446
DOI: 10.26452/fjphs.v3i4.513 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Journal of Pharmaceuticals and Health Sciences, online erschienen am 18.10.2023. Verfasst von {"name":"Rajasekhar Sreerama","email":"ashokreddy1021@gmail.com","affiliation":" und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
To protect the public’s health, the pharmaceutical business must first ensure the efficacy and safety of its products. In this comparative study, the reg- ulatory frameworks for fake and inferior-quality medicines in India and the United States are analysed and contrasted. The study uses a mixed-approaches methodology, combining qualitative and quantitative research methods. Interviews with important figures from pharmaceutical corpora- tions, healthcare organisations, and regulatory authorities are used to collect primary data. These interviews are combined with a thorough analysis of the literature, laws, and case studies that have already been published. We eval- uate the efficacy of corrective measures implemented by regulatory bodies to reduce the dangers associated with fake and subpar medications. The com- parative research identifies the regulatory frameworks of each nation’s strong and weak points, revealing possible areas for development. Suggestions are made for improving inter-agency communication, streamlining inspection processes, and implementing cutting-edge technologies for improved surveil- lance.In the end, this study contributes to the global conversation on drug reg- ulation and public health by illuminating the obstacles and opportunities that India and the USA must overcome in their fight against fake and subpar med- ications. Policy makers, regulatory bodies, and stakeholders in both nations are likely to benefit from the research’s findings, which will help create a more effective and flexible regulatory framework for pharmaceuticals.
Zitieren
APA
Sreerama","email":"ashokreddy1021@gmail.com","affiliation":", N., Kumar","email":"ashokreddy1021@gmail.com","affiliation, N. A., & Nelavala","email":"ashokreddy1021@gmail.com","affil, N. N. (2023). A Comparative Study on the Review and Evaluation of the Regulatory Process of Spurious and not Standard Quality Drugs in Different Countries. Future Journal of Pharmaceuticals and Health Sciences, 3(4), 441-446. https://doi.org/10.26452/fjphs.v3i4.513
Vancouver
Sreerama","email":"ashokreddy1021@gmail.com","affiliation":" N, Kumar","email":"ashokreddy1021@gmail.com","affiliation NA, Nelavala","email":"ashokreddy1021@gmail.com","affil NN. A Comparative Study on the Review and Evaluation of the Regulatory Process of Spurious and not Standard Quality Drugs in Different Countries. Future Journal of Pharmaceuticals and Health Sciences. 2023;3(4):441-446. doi:10.26452/fjphs.v3i4.513
BibTeX
@article{Sreeramaemailashokreddygmailcomaffiliation2023,
author = {Sreerama","email":"ashokreddy1021@gmail.com","affiliation":", "name":"Rajasekhar and Kumar","email":"ashokreddy1021@gmail.com","affiliation, "name":"Somu Ashok and Nelavala","email":"ashokreddy1021@gmail.com","affil, "name":"Audi Narayana},
title = {A Comparative Study on the Review and Evaluation of the Regulatory Process of Spurious and not Standard Quality Drugs in Different Countries},
journal = {Future Journal of Pharmaceuticals and Health Sciences},
year = {2023},
volume = {3},
number = {4},
pages = {441--446},
doi = {10.26452/fjphs.v3i4.513}
}
EUVIMED